mirtazapine has been researched along with Diffuse Parenchymal Lung Disease in 1 studies
Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Most patients had COPD or interstitial lung disease; 52 (81%) completed the trial." | 6.94 | Randomised, double-blind, multicentre, mixed-methods, dose-escalation feasibility trial of mirtazapine for better treatment of severe breathlessness in advanced lung disease (BETTER-B feasibility). ( Bajwah, S; Best, E; Brown, S; Crosby, V; Currow, D; Hart, SP; Higginson, IJ; Johnson, MJ; Lovell, N; Poad, H; Wilcock, A; Yi, D, 2020) |
| "Most patients had COPD or interstitial lung disease; 52 (81%) completed the trial." | 2.94 | Randomised, double-blind, multicentre, mixed-methods, dose-escalation feasibility trial of mirtazapine for better treatment of severe breathlessness in advanced lung disease (BETTER-B feasibility). ( Bajwah, S; Best, E; Brown, S; Crosby, V; Currow, D; Hart, SP; Higginson, IJ; Johnson, MJ; Lovell, N; Poad, H; Wilcock, A; Yi, D, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Higginson, IJ | 1 |
| Wilcock, A | 1 |
| Johnson, MJ | 1 |
| Bajwah, S | 1 |
| Lovell, N | 1 |
| Yi, D | 1 |
| Hart, SP | 1 |
| Crosby, V | 1 |
| Poad, H | 1 |
| Currow, D | 1 |
| Best, E | 1 |
| Brown, S | 1 |
1 trial available for mirtazapine and Diffuse Parenchymal Lung Disease
| Article | Year |
|---|---|
Randomised, double-blind, multicentre, mixed-methods, dose-escalation feasibility trial of mirtazapine for better treatment of severe breathlessness in advanced lung disease (BETTER-B feasibility).
Topics: Administration, Oral; Adult; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administrat | 2020 |